Streptozotocin Diabetes CORRELATION WITH EXTENT OF DEPRESSION OF PANCREATIC ISLET NICOTINAMIDE ADENINE DINUCLEOTIDE
Open Access
- 1 September 1974
- journal article
- research article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 54 (3) , 672-677
- https://doi.org/10.1172/jci107805
Abstract
The diabetogenic activity of streptozotocin has been correlated with a reduction in pyridine nucleotide synthesis in the mouse pancreatic islet. To determine the specificity of this reduction for diabetogenicity, a comparative study of streptozotocin, its cytotoxic moiety, 1-methyl-1-nitrosourea, and alloxan was performed. Streptozotocin administered intraperitoneally (i.p.) producd a dose-related reduction in islet NAD which was proportional to the degree of diabetogenicity. A diabetogenic dose, 200 mg/kg, attained a peak plasma N-nitroso intact streptozotocin concentration of 0.224 μmol/ml and reduced the mean islet NAD from a control of 0.78 to 0.15 pmol. At borderline, 150 mg/kg, and nondiabetogenic, 100 mg/kg, doses, plasma concentrations reached 0.161 and 0.136 μmol/ml, and NAD was 0.36 and 0.86 pmol/islet, respectively. 1-Methyl-1-nitrosourea, 100 mg/kg, attained a maximum N-nitroso intact 1-methyl-1-nitrosourea concentration of 0.162 μmol/ml and reduced the mean NAD to 0.58 pmol/islet, and was nondiabetogenic; 200 mg/kg attained a peak plasma concentration of 0.344 μmol/ml and depressed NAD to 0.38 pmol/islet, and was inconsistently diabetogenic. Islet NAD of 0.4 pmol/islet or greater is required for integrity of the beta cell. A diabetogenic dose of alloxan, 500 mg/kg, did not depress NAD, 0.85 pmol/islet, therefore confirming that its mechanism of diabetogenicity differs from that of streptozotocin. In vivo uptake of [methyl-14C]streptozotocin by islets was 3.8 times that of [methyl-14C]-1-methyl-1-nitrosourea, whereas uptake by the exocrine pancreas favored 1-methyl-1-nitrosourea over streptozotocin 2.4:1. The decreased islet uptake of 1-methyl-1-nitrosourea correlates with the 3.5 times increased molar dosage required to produce islet NAD depression comparable to that of streptozotocin, 150 mg/kg. These studies indicate that the glucose carrier of streptozotocin facilitates uptake of its cytotoxic group, 1-methyl-1-nitrosourea, into islets.Keywords
This publication has 19 references indexed in Scilit:
- Streptozotocin for malignant insulinomas and carcinoid tumor. Report of eight cases and review of the literature.1973
- Islet Cell Tumors: Current Concepts and ManagementAnnals of Internal Medicine, 1973
- Influence of Nicotinamide and Pyridine Nucleotides on Streptozotocin and Alloxan Induced Pancreatic B Cell CytotoxicityDiabetes, 1973
- Effect of sulfhydryl reagents on permeability of toadfish islet tissueAmerican Journal of Physiology-Legacy Content, 1970
- Streptozotocin Diabetes: Time Course of Irreversible B-Cell Damage; Further Observations on Prevention by NicotinamideExperimental Biology and Medicine, 1970
- 1-methyl-1-nitrosourea and dialkylnitrosamine depression of nicotinamide adenine dinucleotide.1969
- Streptozotocin: depression of mouse liver pyridine nucleotides.1968
- The use of nicotinamide to modify the toxicity of streptozotocin diabetes without loss of antitumor activity.1967
- Studies of the Diabetogenic Action of Streptozotocin.Experimental Biology and Medicine, 1967
- Structure of streptozotocinJournal of the American Chemical Society, 1967